Hamamatsu Continues to Seek Foothold Outside of Japan for HT Screening Tech | GenomeWeb

This article has been updated from a previous version, which incorrectly stated that SciClone Pharmaceuticals is a customer of the Hamamatsu FDSS 6000.

PHILADELPHIA — Japanese photonics component and instrumentation maker Hamamatsu is "making progress" in its attempt to gain US and European market penetration for its Functional Drug Screening System 6000, a high-throughput plate reader for multiple cell-based assay applications, a company official told CBA News at the World Pharmaceutical Congress held here last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.